Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 143.75 · gapped above the open, never looked back. High/low 144.99 at 4:45 am ET, 143.99 at 4:00 am ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of MRNA revenue | Skew |
|---|---|---|---|
| PSNLPersonalis, Inc. | 22.00% | 0.79% | 28× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under the terms of the Moderna Agreement, Moderna made an upfront payment to us of $35.0 million, including $5.0 million of pre-paid research funding which was subsequently utilized by Moderna.”
FILING10-K0001193125-26-107146cik 0001501989disclosed by CTMX
“The following table shows customers that made up at least 10% of total revenue in each year presented: Year Ended December 31, 2025 2024 Moderna, Inc. 22% 28%”
$15M relationship28× more of PSNL’s book than MRNA’s
basisPSNL fy2025 · closed 2025-12 $70MMRNA fy2025 · closed 2025-12 $1.9B
FILING10-K0001193125-26-076615cik 0001527753disclosed by PSNL
“Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.”
FILING10-K0002019410-26-000016cik 0002019410disclosed by CAI
“Under the terms of the Moderna Settlement Agreement, Moderna will make an aggregate $950.0 million Noncontingent Settlement Payment to us and Genevant on or before July 8, 2026.”
FILING10-K0001447028-26-000017cik 0001447028disclosed by ABUS
“31, 2025, the Group had two revenue-generating strategic collaboration agreements in place, one with Bristol-Myers-Squibb ("BMS") and one agreement with ModernaTX, Inc. ("Moderna"), which both are in pre-clinical stage.”
FILING20-F0001193125-26-092529cik 0001809196disclosed by IMTX
“mRNA-2808 utilizes Autolus' proprietary binder that was licensed to Moderna in 2022.”
FILING10-K0001730463-26-000038cik 0001730463disclosed by AUTL
“In September 2022, Merck exercised its option for personalized cancer vaccines (PCVs), including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement, also referred to as the INT Agreement).”
FILING10-K0001682852-26-000033cik 0001682852
“In addition, we have built and manage mRNA manufacturing facilities in the United Kingdom, Canada and Australia. These facilities were fully licensed in 2025, and the government in each of these countries has entered into a multi-year commitment to purchase mRNA products from us.”
FILING10-K0001682852-26-000033cik 0001682852
“In addition, we have built and manage mRNA manufacturing facilities in the United Kingdom, Canada and Australia. These facilities were fully licensed in 2025, and the government in each of these countries has entered into a multi-year commitment to purchase mRNA products from us.”
FILING10-K0001682852-26-000033cik 0001682852
“In addition, we have built and manage mRNA manufacturing facilities in the United Kingdom, Canada and Australia. These facilities were fully licensed in 2025, and the government in each of these countries has entered into a multi-year commitment to purchase mRNA products from us.”
FILING10-K0001682852-26-000033cik 0001682852
“Fill-and-finish of the vaccine, including the new single-use pre-filled syringes, is completed by Novocol Pharma in Cambridge, Ontario.”
FILING10-K0001682852-26-000033cik 0001682852
“In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited (together, Vertex).”
FILING10-K0001682852-26-000033cik 0001682852
Watchlist prices, news filtered to it, and its next report on your desk.
Moderna, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Moderna, Inc. has 7 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Moderna, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
MRNA (Moderna, Inc.) has 7 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: CTMX +1.49%, in healthcare.